Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Martin Moylan
St. Paul, Minn.

Boston Scientific to settle patent disputes for $1.7b

Go Deeper.

Create an account or log in to save stories.

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Boston Scientific, which has extensive medical device manufacturing operations in the Twin Cities, will pay $1.7 billion to Johnson & Johnson to settle patent disputes.

The three disputed patents date back to 2003. They involve drug-eluting heart stents--metal tubes that prop open clogged arteries and release a drug to help keep the blood vessel open.

The hefty price tag surprised some analysts, but Jan Wald, an analyst with Noble Financial Group, says the settlement makes sense. Wald says Boston Scientific has made a lot of money off the disputed patents and seems positioned to make more.

"The company has been able to generate maybe $6 billion of profits off a drug-eluting stent that it now has to pay $1.7 billion for," she said.

Boston Scientific will pay Johnson & Johnson $1 billion Monday and the rest by the first week of January 2011. Some analysts speculate the settlement may spur job cuts, but the company wouldn't comment on the impact of the settlement.